| Valiltramiprosate Shows Favorable Safety Outcomes with Low ARIA Risk and Evidence of Neurovascular Protection in APOE4/4 Alzheimer’s Patients The post Alzheon to Present Evidence of Neurovascular Protection from Trials with Oral Valiltramiprosate in APOE4/4 Alzheimer’s Patients Leading to Reduced Brain Edema and Microhemorrhage Risk at 2026 American Academy of Neurology Meeting in Chicago, Illinois appeared first on Alzheon | Preserving Future Memories . |